$NEO NeoGenomics Reports Revenue of $18.2 Mill
Post# of 63700
Posted On: 04/23/2014 7:49:54 AM
$NEO
[url=First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI"
edits relating to billing Medicare for FISH testing. ]NeoGenomics[/url] Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter
Company Increases Revenue and EPS Guidance for the Full-Year
First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI" edits relating to billing Medicare for FISH testing.
[url=First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI"
edits relating to billing Medicare for FISH testing. ]NeoGenomics[/url] Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter Company Increases Revenue and EPS Guidance for the Full-Year
First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI"
edits relating to billing Medicare for FISH testing. 
(0)
(0)Scroll down for more posts ▼